InvestorBrandNetwork (IBN) Content Platform

• A report published by Allied Market Research noted that in 2019, the global challenger bank market generated $20.4 billion and should post over $471 billion in revenue by 2027
• This growth will be attributed to the reduced associated costs, accessibility and overall convenience that the challenger bank market offers
• Through its strategic acquisition approach, FEXD is advancing this sector while offering consumers the services and flexibility they need
• By doing so, FEXD hopes to reduce poverty, improve the lives of the unbanked, and offer security and saving options for migrant workers

Fintech Ecosystem Development (NASDAQ: FEXD) is, through strategic mergers and acquisitions, helping accelerate the growth of the challenger bank market. In turn, the company is making financial services affordable and accessible, particularly to individuals in emerging markets, who grossly lack this access compared to their counterparts in developed regions. This focus is helping FEXD carve out a significant market share and leave an indelible mark, even as the world gradually shifts to digital currency.

In a report published by Allied Market Research, it was noted that, in 2019, the global challenger bank market generated $20.4 billion. The report then estimated that, by 2027, this market would post over $471.0 billion in revenue, representing a CAGR of 48.1% over the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

The Sustainable Green Team (OTCQX: SGTM), a provider of environmentally conscious solutions in the arbor care, disposal and recycling industries, will be featured in an upcoming episode of FMW Media’s “New to the Street,” a nationally syndicated program. The company is one of five to be showcased on New to the Street’s 503rd broadcast, airing at 3:30 p.m. ET on Saturday, Aug. 18, 2023. The company’s Director of Administration Brian Rivera and CEO Brian Meier will join host Jane King to discuss SGTM’s environmentally conscious solutions, strong team and sustainable business practices of converting waste into usable organic products.

To view the full press release, visit https://ibn.fm/JeFht

About Sustainable Green Team Ltd.

The Sustainable Green Team is a wholesale manufacturer and national supplier of wood-based mulch, lumber products and soil, including soil amendment products HumiSoil(R) and XLR8(R). The company sells directly to mass merchandisers, home centers, hardware stores, nurseries, garden centers, convenience stores, food stores, and wholesale distributors. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that has been historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation. For more information about the company, visit www.TheSustainableGreenTeam.com.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Flora (NASDAQ: FLGC), a global consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000+ points of distribution, has announced its entry into a partnership with TruHC Pharma, a medical cannabis expert based in Hamburg, Germany. TruHC holds an EU-GDP certification as an importer, distributor and manufacturer of medical cannabis, and operates a production facility with a cutting-edge cannabis laboratory for which an EU-GMP license is expected by the end of September. Hendrik Knopp, a respected lawyer, accomplished entrepreneur and leader who has been pivotal in establishing Germany’s medical cannabis landscape, along with the TruHC team, join the Flora family. “I am delighted to welcome Hendrik Knopp and the TruHC team to the Flora group. Their expertise and achievements within the industry, particularly in pioneering medical cannabis in Germany, make them invaluable partners,” said Clifford Starke, chief executive officer of Flora. “We are poised to execute our strategic business plan and capture a meaningful market share in Germany.”

To view the full press release, visit https://ibn.fm/1u63q

About Flora Growth Corp.

Flora is a global consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000+ points of distribution. For more information on Flora, visit www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a company working to develop a global financial technology ecosystem comprising a network of mobile money platforms, technologies, applications, products, and services. “The technologies, the company’s website states, are meant to ‘make it easy to move money across borders to almost any place in the world, in virtually any currency, using your mobile phone or laptop.’ FEXD aims to use emerging technologies such as blockchain, web 3.0, artificial intelligence (“AI”), and the metaverse to reduce costs and accelerate the processing of money transfers, loans and other lifestyle services, which will benefit consumers and businesses in many countries, according to Dr. Sainful Khandaker, CEO, president and founder of FEXD,” a recent article reads. “With a goal of leveraging the power of such emerging technologies to benefit businesses and consumers downstream, FEXD is not only developing platforms and applications that support cashless transactions but also seeking to acquire and merge with high-growth global fintech companies primarily operating in South Asia with a high volume of customers and extensive network of agents.”

To view the full article, visit https://ibn.fm/XQZqy

About Fintech Ecosystem Development Corp.

Fintech Ecosystem Development is a special purpose acquisition company formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector. The company is sponsored by Revofast LLC and the management team led by CEO, president and founder Dr. Saiful Khandaker and a group of experienced fintech business and technology innovators. For more information about the company, please visit www.FintechEcosys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Sharing Services’ (OTCQB: SHRG) wholly owned subsidiary, MyTravelVentures, recently completed its first-ever Venture Trip at the Sensira Resort and Spa in Cancun, Mexico. “According to a report from the U.S. Travel Association, total travel spending in May improved to 1.4% above May 2022 levels and was up 5.5% year-to-date through May 2023. In addition, air travel demand remained above May 2022. Furthermore, Forbes is reporting that, even with continuing inflation, layoffs and a potential recession, ‘2023 travel trends show no slowdown,’” a recent article reads. “This is the ideal climate for MyTravelVentures to prosper and grow. The company’s subscription-based membership plan, which is available for a recurring monthly fee with no contracts or commitments, offers members full access to exclusive deals across the travel industry. These deals represent savings of up to 65% on a variety of services, including flights, hotels, transportation and events; the plan even includes nontravel-related services such as retailer discounts, cash-back programs and telehealth services. Even more exciting are the company’s curated, all-inclusive group vacation packages. These exclusive Venture Trips offer premium resort getaways with immersive experiences.”

To view the full article, visit https://ibn.fm/fefoY

About Sharing Services Global Corporation

Sharing Services is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Additional information is contained in the company’s 10-Q and 10-K filings with the Securities and Exchange Commission. For more information, visit www.SHRGInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced that Hector Lombard, a professional mixed martial artist, bodybuilder, UFC fighter, and former Olympic judoka, has signed on as a brand ambassador for Safety Shot, the company’s first-of-its-kind rapid alcohol detoxification drink. Lombard is a social media influencer that has amassed a following of 3 million across platforms including Instagram and X (formerly Twitter). As a Cuban-Australian, Lombard’s global audience of sports and fitness enthusiasts is a key target demographic for Safety Shot. “We’re excited to have Hector come on board as Safety Shot’s first brand ambassador,” said Jupiter Wellness CEO Brian John. “As we gear up for launch in the fourth quarter, we plan to engage with many other brand ambassadors who make wellness a priority and communicate their positive message to a wide and diverse audience.”

To view the full press release, visit https://ibn.fm/KFwvi

About Jupiter Wellness Inc.

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, psoriasis and vitiligo. Revenue is generated through the sales of OTC and consumer products and licensing royalties. The company recently acquired Safety Shot, the world’s first blood alcohol detox drink. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at JupiterWellness.com/email-alerts and by following Jupiter Wellness on Twitter and LinkedIn.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Aditxt (NASDAQ: ADTX), a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system, announced an important update regarding its innovation programs and strategic M&A initiatives. The shareholder update provides the company’s planned strategy for achieving commercial scale. “Aditxt takes a stakeholder-driven approach to developing and deploying some of the most promising health innovations such as Pearsanta’s immune monitoring platform and Adimune’s immune modulation therapeutic,” Amro Albanna, Aditxt CEO, chairman and co-founder states in the update. “Our goal is to get our current programs to reach key clinical or commercial stage and expand our portfolio of innovations to address additional markets such as oncology and neurology.”

The company also issued a correction and replacement of its Aug. 17 announcement of a 1-for-40 reverse stock split. According to the update, the “First paragraph, first sentence of release should read: Aditxt, Inc. (NASDAQ: ADTX) (‘Aditxt’ or the ‘Company’), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock…”

To view the full press releases, visit https://ibn.fm/51gvr and https://ibn.fm/fQzl0

About Aditxt Inc.

Aditxt is a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system. Headquartered in Richmond, Virginia, the company has operations in Silicon Valley, California, and New York, New York. Aditxt’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire its mission. Aditxt’s diverse innovation portfolio includes: Adimune(TM), developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir(TM), focused on identifying, developing, and commercializing new ways to treat infectious diseases; and Pearsanta(TM), which offers personalized immune monitoring for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy. For more information, visit the company’s websites at www.Aditxt.com, www.Adimune.com and www.Pearsanta.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• FEXD is developing a global financial technology ecosystem that will address unmet mobile money needs in developing and industrialized markets and make it easier and more affordable to transact digitally
• The company aims to use emerging technologies such as AI to reduce costs associated with and fast-track the processing of money transfers and loans
• AI is a powerful technology that has been positively associated with the improvement in digital financial inclusion
• The technology is used in credit risk assessment, investment-related decision-making, fraud detection and prevention, prediction, and customer service
• With FEXD eying digital money transfers, which are unfortunately prone to cyber threats and fraud attempts, the company aims to tap into the power of AI to promote security and efficiency, thus driving digital financial inclusion

Long before large language models (“LLMs”) like ChatGPT and Bard democratized artificial intelligence (“AI”), this powerful technology existed and was deployed in different industries. The banking, financial services, and insurance (“BFSI”) industry, for instance, is recognized as one of the earliest and most prominent adopters of the technology, having first incorporated some form of AI about three and a half decades ago (https://ibn.fm/wZMQi). But the rise of new frontiers in AI, such as generative AI, of which LLMs are part, has created new opportunities that incumbents and startups can use to their benefit.

The earliest implementation of AI in the BFSI space was in the domain of credit risk assessment. And many years on, financial services companies such as banks and lenders still use the technology to assess the creditworthiness of customers. But, compared to the formative years, AI has evolved, thanks in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has announced that it will effect a 1-for-40 reverse split of its common stock effective as of 9:30 a.m. Eastern Time on Aug. 18, 2023. Commencing with the opening of trading on the Nasdaq Capital Market on Aug, 18, the company’s common stock will trade under the same symbol ADTX on a post-split basis. The reverse stock split was approved by the company’s stockholders at the annual meeting held on Aug. 16, 2023, with the final ratio determined by the company’s board of directors.

To view the full press release, visit https://ibn.fm/JJfQD

About Aditxt Inc.

Aditxt is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. Headquartered in Richmond, Virginia, the company has operations in Silicon Valley, California, and New York, New York. Aditxt’s mission “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire its mission. Aditxt’s diverse innovation portfolio includes: Adimune(TM), aimed at developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir(TM), focused on identifying, developing, and commercializing new ways to treat infectious diseases; and Pearsanta(TM), which intends to offer personalized immune monitoring for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy. For more information, visit the company’s websites at www.Aditxt.com, www.Adimune.com and www.Pearsanta.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Siyata Mobile (NASDAQ: SYTA, SYTAW) (TSX.V: SIM), a global vendor of Push-to-Talk (“PTT”) over Cellular (“PoC”) and cellular signal booster solutions, is capturing industry attention with its most recent financial report; the report included revenues of $2.7 million, which is a significant increase of 180% compared to the same period 2022. According to the report, much of the growth comes from sales of Siyata Mobiles flagship product, the SD7, which brought in $1.9 million in revenue during Q2 2023. The company noted that the sharp increase in sales is an indication of the increasing demand and popularity of the SD7 handset among customers. In addition to the increase in revenue, the report showed gross profits of $804,000, equivalent to 29.7% of revenues, a substantial improvement compared to the previous year’s $109,000, which accounted for 11.2% of revenues. The company noted that this increase was largely attributed to a strategic shift in selling more SD7 handsets. With these growing numbers as a backdrop, combined with the company’s cash on hand and experienced sales team, Siyata says its market cap is undervalued at approximately $7 million.

“Growth continued to accelerate in the second quarter with a 180% year-over-year increase in revenue on strengthening sales of our mission-critical PoC (MCPTT) SD7 solution,” said Siyata Mobile founder and CEO Marc Seelenfreund in the press release. “Adoption of our critical communications devices is expanding. We have received purchase orders for the SD7 handset and its accessories of more than $5 million since the start of 2023, and our resellers also anticipate an increase in demand. Just as important, the increase in orders reaches beyond emergency services to include education, healthcare, industrial, and enterprise use cases among others. Given our performance in the first half of the year and our expanding sales pipeline, we are increasingly optimistic that 2023 will be a strong growth sales year for Siyata.”

To view the full press release, visit https://ibn.fm/6B7dQ

About Siyata Mobile Inc.

Siyata Mobile is a B2B global vendor of next-generation, Push-to-Talk over cellular devices, cellular booster systems and video monitoring systems. Its portfolio of in-vehicle and rugged devices enable first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to increase situational awareness and save lives. The company’s portfolio of enterprise-grade and consumer cellular-booster systems enables first responders and enterprise workers to amplify cellular signal in remote areas, inside structural buildings where signals are weak and within vehicles for the maximum cellular signal strength possible. For its video monitoring system, Siyata integrates software that we license with off-the-shelf hardware providing our customers with an integrated advanced camera system for management and visual monitoring of their fleet vehicles. For more information about the company, visit www.SiyataMobile.com or www.UnidenCellular.com.

NOTE TO INVESTORS: The latest news and updates relating to SYTA are available in the company’s newsroom at http://ibn.fm/SYTA

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

SRM Entertainment (NASDAQ: SRM), a company that designs, develops and manufactures custom toys and souvenirs for the world’s largest theme parks and entertainment venues, has closed on its initial public offering. The offering was comprised of 1,250,000 shares of its common stock that were offered to the public at an initial price of $5 per share. According to the announcement, SRM shares began trading on the NASDAQ Capital Market on Aug. 15, 2023. The offering resulting in gross proceeds of $6.25 million, before standard underwriting discounts and commissions and other related expenses are deducted. The announcement also noted that the company has granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of common stock at the same public offering price, minus underwriting discounts and commissions.

To view the full press release, visit https://ibn.fm/BBTNo

About SRM Entertainment Inc.

SRM Entertainment designs, develops and manufactures custom toys and souvenirs for the world’s largest theme parks and entertainment venues. The company provides exclusive custom products that are available worldwide at venues such as Walt Disney Parks and Resorts, Universal Studios, SeaWorld and other attractions. The company also recently launched its retail product line, which includes patented SMURFS Sip with Me cups. For additional information about this company, please visit www.SRMEntertainment.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Pressure BioSciences (OTCQB: PBIO) today announced that its CEO and President Richard T. Schumacher and Director of Marketing and Sales John B. Hollister are the featured speakers at an online webinar scheduled for 11 a.m. ET on Thursday, Aug. 17, 2023. The webinar will showcase an overview of Pressure BioSciences and its core technologies and products, as well as outline the transformative impact of the company’s powerful UltraShear platform and its multiple applications in health and wellness. “The combination of our UltraShear launch progress, the powerful enhancement that UltraShear offers in multiple billion-dollar industries, the impending publication of UltraShear bioavailability study results, and efforts focused on the improvement of our balance sheet and future revenue, provide a powerful forward-focused opportunity for our investors,” Schumacher said. “We continue to work with multi-billion-dollar international conglomerates, well-funded startups, and many companies in between, as we facilitate the adoption of UltraShear. We believe our IP estate is worth many times our current enterprise value. During my professional career, I have priorly founded/co-founded three successful public companies, yet in my opinion, none had close to the potential that we have in PBIO. For these and other reasons, we believe PBIO’s future is both exciting and bright.”

To view the full press release, visit https://ibn.fm/kUBHt

About Pressure BioSciences Inc.

Pressure BioSciences is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Its products utilize both constant and alternating pressure. The company’s patented enabling technology platform, Pressure Cycling Technology (“PCT”), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterrorism applications. The company has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing it to enter the bio-pharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology(TM) (UltraShear(TM)) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information about the company, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, is taking steps to begin production of its newly acquired Safety Shot product, the world’s first blood alcohol detox drink. The company has engaged an experienced contract beverage manufacturer/packer with facilities across the United States for production; the company anticipates the drink will be available in a 12-ounce sleek can. In addition, company officials noted that Jupiter Wellness has created a multichannel strategy designed to dominate e-commerce, win retail shelf space and establish longstanding ties with key distribution and sales partners. Members of the media are invited at attend the unveiling of the new product, slated for Sept. 15, 2023, at 4 p.m. at company headquarters in Jupiter, Florida. The company noted that its newest offering pushes the boundaries of innovation by creating an exciting new product category in the growing hangover remedies market: rapid alcohol detoxification. Its Safety Shot offering is designed to reduce intoxication levels by one-half within 30 minutes using a patented formula that accelerates the process of converting alcohol into sugar in the body. “I have given Safety Shot to dozens of people now and trying the drink is believing in the drink,” said Jupiter Wellness CEO Brian John in the press release. “We look forward to allowing members of the media to come see Safety Shots’s incredible results for themselves.”

To view the full press release, visit https://ibn.fm/fsByD

About Jupiter Wellness Inc.

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, psoriasis and vitiligo. Revenue is generated through the sales of OTC and consumer products as well as licensing royalties. The Company recently acquired Safety Shot, the world’s first blood alcohol detox drink. For additional information about this company, visit www.JupiterWellnessInc.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Nemaura (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today announced SFDA (Saudi Food and Drug Authority) approval of sugarBEAT(R), its non-invasive wearable glucose sensor. According to the update, the news comes after a year of liaisons with the SFDA through TPMENA, the company’s licensee in the Middle East. This is seen as a major breakthrough in product commercialization in the largest territory in the Middle East, and a region with one of the world’s highest diabetes prevalence rates. Based on a report in 2021 by the Economist Intelligence Unit, nearly 4.5 million people, or 18.3% of the adult population in Saudi Arabia, have diabetes. This compares to a global average of 9.3%. Further, it is estimated that 39% of adults with diabetes in Saudi Arabia are unaware that they have the condition, leaving them at higher risk of complications without management. This segment of nearly 9 million is ideally placed to benefit from sugarBEAT(R) sensors within a general metabolic health improvement program. Such a program specifically addresses obesity to avoid diabetes and other complications and has shown efficacy within trials with the U.K.’s National Health Service.

To view the full press release, visit https://ibn.fm/wA9uu

About Nemaura Medical Inc.

Nemaura is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA. proBEAT combines noninvasive glucose data processed using artificial intelligence and a digital health care subscription service as a general wellness product as part of its BEAT(R) diabetes program that is currently undergoing pilot studies. Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has begun preparations for good manufacturing practices (“GMP”) production of a capsule formulation of CYB003, its proprietary deuterated psilocybin analog in development for the potential treatment of Major Depressive Disorder (“MDD”). According to the announcement, the formation is stable, dose and patient friendly, and is commercially scalable. The company noted that it anticipates shipping the CYB003 capsules to clinical sites by first quarter 2024. “The development of a capsule formulation of CYB003 represents a meaningful advancement toward a commercially viable and more convenient dosing option that is potentially suitable for a future phase 3 trial,” said Cybin CEO Doug Drysdale in the press release. “We are very pleased with the progression of our CYB003 program in MDD thus far. Preparations for GMP manufacturing of CYB003 capsules continue to build on our efforts to progress an improved treatment option for people with major depressive disorder. Coupled with our partnership with Worldwide Clinical Trials, a global CRO with deep expertise in psychedelic clinical trials, and the development of EMBARK(CT), a scalable model of our psychedelic facilitation program, these efforts are a testament to our clinical execution and capabilities at each step along our development pathway.”

To view the full press release, visit https://ibn.fm/rFsom

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today provided an interim analysis from its ongoing phase 1B trial of Next Generation Capecitabine (“NGC-Cap”) in patients with gastrointestinal cancer, which identifies a personalized treatment approach that may yield improved safety and treatment efficacy. “The presence of DPD as expressed by the plasma concentration of FBAL provides us important information that may confirm our hypothesis that we can optimize our dosing of NGC-Cap to maintain efficacy and minimize side effects by carefully tracking each individual patient following an initial dosing of our novel chemotherapy,” said Sian Bigora, Pharm.D., Processa’s chief development and regulatory officer. “By following the chemical concentration in the plasma in each patient, we may be able to actually optimize therapy through individualization of each patient’s dosing regimen. We find these results, albeit early results, to be very encouraging.”

To view the full press release, visit https://ibn.fm/LFk1N

About Processa Pharmaceuticals Inc.

Processa is a clinical stage pharmaceutical company focused on developing the Next Generation Chemotherapy drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also increase the probability of FDA approval for its Next Generation Chemotherapy drugs. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its approach to drug development is based on more than 30 years of drug development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. Using its proven Regulatory Science Approach, Processa has experience defining the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. The advantages of Processa’s Next Generation Chemotherapy drugs are expected to include fewer patients experiencing side effects that lead to dose discontinuation; more significant cancer response; and a greater number of patients who will benefit from each Next Generation Chemotherapy drug. Currently in its pipeline are three Next Generation Chemotherapy drugs: Next Generation Capecitabine (“PCS6422” and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers), Next Generation Gemcitabine (“PCS3117” to treat pancreatic, lung, ovarian, breast, and other cancers), and Next Generation Irinotecan (“PCS11T” to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers). For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

GolfLync, the premier social media platform for golf enthusiasts, is proud to announce a significant milestone, surpassing 50,000 members across the United States. The exponential growth is a testament to the platform’s ability to bring golfers together, fostering vibrant golfing communities and connections that continue to flourish.

From local golf clubs to nationwide networks, GolfLync’s Virtual Golf Clubs(TM) (“VGC”) have transformed the way golfers connect, share, and experience the game they love. Members are embracing the platform’s innovative features, with private and public VGCs serving as hubs for planning…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

EverGen (TSX.V: EVGN) (OTCQX: EVGIF) today announced plans to release its 2023 second quarter financial results after market close on Aug. 23, 2023. At 10:00 a.m. ET on the following day, Aug. 24, EverGen will hold a results and corporate update conference call, hosted by Chief Executive Officer Chase Edgelow. Interested parties should visit https://ibn.fm/6TXZK to register for the event and access the webcast.

To view the full press release, visit https://ibn.fm/pcIwO

About EverGen Infrastructure Corp.

EverGen, Canada’s renewable natural gas (“RNG”) infrastructure platform, is combating climate change and helping communities contribute to a sustainable future. Headquartered on the West Coast of Canada, EverGen is an established independent renewable energy producer, which acquires, develops, builds, owns and operates a portfolio of renewable natural gas, waste to energy and related infrastructure projects. EverGen is focused on Canada, with continued growth expected across other regions in North America and beyond. For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Blue Hat Interactive (NASDAQ: BHAT) has completed the issue of $29.8 million of ordinary shares. According to the announcement, the company anticipates continued development of the commodities trading business, especially in trading gold and jewelry, which will create sustainable values for global shareholders. “The completion of this issuance marks a significant development for BHAT, continuing the company’s transformation to commodity trading since the third quarter of 2022,” said BHAT CEO Xiaodong Chen in the press release. “The company has appointed Mr. Pan Weicheng as the CSO in May 2023. Under the leadership of Mr. Pan, a new business system was established — commodity trading with artificial intelligence analysis. At the same time, BHAT has also divested its Variable Interest Entity (‘VIE’) structure within mainland China. These adjustments are strategic and enduring. BHAT will gradually shift towards international growth. In the future, BHAT plans to expand and shift its business’s focus to Southeast Asia and the United States. The presence and development of artificial intelligence is inevitable. Thus, utilizing AI technology to influence the existing commodity trading framework is at the core of our new strategy. We are enthusiastic about this forward-thinking endeavor. We envision a working model that is fully implemented and results in positive outcomes, which we have already begun to achieve in the past three quarters.”

To view the full press release, visit https://ibn.fm/n6MkF

About Blue Hat Interactive Entertainment Technology

Blue Hat is developing a commodity trading with artificial intelligence analysis focus.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Financial analysts, business owners, investors, financial institutions, and regulators, are invited to attend FinovateFall, held in the Marriott Marquis Times Square, New York City, September 11-13, 2023. The much-awaited event is returning to bustling New York City. Featuring interactive sessions, live demos, and unlimited entertainment options, FinovateFall promises to be a fintech extravaganza that sparks innovation and creativity.

Important thought leaders will share their perspectives on the future of finance through engaging seminars and live demos showing the latest in fintech developments, all while offering off-hours NYC entertainment opportunities that will keep participants captivated. New York’s unmatched…

Read More>>

To learn more, please visit https://ibn.fm/sLe8Y.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, is reporting its financial and operating results for the second quarter and six-month period ended June 30, 2023. Highlights of the report include a 31% decrease in operating expenses quarter over quarter and 25% year to date, a reflection of the company’s cost-cutting initiatives; revenue of $3.4 million for the Q2 2023 and $7.3 million for the six-month period, compared to $4.2 million and $7.8 million for the three and six months ended June 30, 2022, respectively; and gross profit of $2.1 million for the quarter and $4.4 million for the six-month period, compared to $2.6 million and $5.1 million for the comparable periods in 2022, respectively. The company reported cash and cash equivalents totaled $3.9 million on June 30, 2023. Operational highlights include an estimated 40,000 patients being treated with the Vivos Method and more than 1,800 dentists trained in the use of the Vivos Method and related value-added services as well as the announcement of the results of a clinical observational study on the application of the POD(R) (now being rebranded as the Vida) in the treatment and prevention of migraine headaches.

“Throughout this year, we significantly reduced our cash burn, which led to a 31% second quarter over quarter, and 25% year over year reduction in operating expenses,” said Vivos chair and CEO Kirk Huntsman in the press release. “At the same time, we expanded our product offerings to address a broader spectrum of patient needs and price points to drive revenue growth. This included our acquisition of certain key patents, trademarks, product rights and trade secrets earlier in 2023, which filled a gap in our product offerings to providers and patients. We continue to believe that these developments will allow us to begin to see revenue improvement here in the second half of 2023. . . . Through the combination of our strategic revenue initiatives, internal operating cost reductions and new capital raising initiatives, we believe we have positioned Vivos to achieve revenue growth and, ultimately, cash-flow positive operations and profitability in the foreseeable future. In summary, while the larger economic and market environment is creating challenges for both the medical and dental communities, Vivos has taken steps to address those challenges, and our long-term growth drivers remain in place.

To view the full press release, visit https://ibn.fm/7DdAx

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective in the treatment of more than 40,000 patients worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.Vivos.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

VPR Brands (OTC: VPRB), a licensing company owning patents and trademarks as well as a market leader for the design and sale of electronic cigarettes, or vaporizers, for nicotine, cannabis and cannabidiol (“CBD”) and other related accessories such as lighters, is reporting its second-quarter 2023 financial results. Highlights of the report show increased revenues and record profits when compared to previous quarters. The company noted that while it was able to increase Q2 2023 revenues over 2022 by an estimated $1 million to $1,909,529, and year-to-date six-month revenue by more than $2 million to $4,990,550, it was able to reduce operating expenses for the two time periods as well. The report showed that net income for VPR Brands increased to more than $928,322 in Q2 2023, up from $73,733 in Q2 2022 and $953,636 year to date, compared to a net loss of $73,508 for the six-month period ending June 30, 2022. “We have been able to successfully license and monetize our ELF brand trademark this year while aggressively protecting the mark in the courts and creating a monumental asset for the company and we are now focusing on developing business for our other trademarks as well,” said VPR Brands CEO Kevin Frija in the press release. “We believe partnering as a Licensor with experienced and well capitalized licensees to expand our brand portfolios business is the model that will work best for the company in the long run.”

To view the full press release, visit https://ibn.fm/wSX25

About VPR Brands LP

VPR Brands is a technology company, as well as an IP holding company. The company is engaged in various monetization strategies of a U.S. patent that the company owns covering electronic cigarette, electronic cigar and personal vaporizer patents, as well as a patent for an inverted pocket lighter. The company also has several trademarks (ELF, PHANTOM, HRB, VPOD, VAPOR X, and RIPPER) for which it is also engaged in licensing and various monetization strategies. VPR Brands also designs, develops, markets and distributes products, including the HoneyStick brand of vaporizers and the Goldline CBD products, oriented toward the cannabis markets. This allows the company to capitalize on the rapidly growing expansion within the cannabis markets. The company is also identifying electronic cigarette companies that may be infringing its patents and trademarks and exploring options to license and/or enforce those patents. The company is now also selling DISSIM brand pocket lighters for which it holds a U.S. patent and patents pending. The company also has patents pending in the cigar accessory space and sells these proprietary accessories. For more information about the company, visit www.VPRBrands.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, has announced the date for the conference call to discuss financial results for the second quarter ended June 30, 2023. The call had initially been scheduled for Aug. 14, 2023, but has been rescheduled for today at 6 p.m. ET. According to the announcement, company officials will host the call to review the company’s financial results and provide an overview of the company’s recent milestones and developments. Those interested in accessing the call can dial 877-451-6152 (toll free) or 201-389-0879 (international callers). A replay of the call, which will be available until Aug. 30, 2023, will be available shortly after the call concludes. The replay can be accessed by dialing 844-512-2921 (toll free) or 412-317-6671 (international callers). The passcode for both the live and replay calls is 13740723. A live webcast of the call is also available.

“As previously disclosed, the rescheduling was the result of the company and its independent registered public accounting firm requiring additional time to review certain disclosures related to the company’s accounting for and disclosures related to the company’s Employee Retention Tax Credit previously received under Section 2301 of the Coronavirus Aid, Relief, and Economic Security Act of 2020,” the company stated in the press release.

To view the webcast, visit https://ibn.fm/ZP4Ek

To view the full press release, visit https://ibn.fm/HeWvF

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective in the treatment of more than 40,000 patients worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.Vivos.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Intercept Music, a wholly owned subsidiary of Sanwire (OTC: SNWR), has announced the launch of its latest software version, now incorporating cutting-edge artificial intelligence (“AI”) technology into the music marketing process. As a frontrunner to introduce AI integration, Intercept Music is empowering artists and musicians to level the playing field and market their music on-par with major labels. “We are thrilled to introduce the world’s first AI-integrated music marketing software,” said CEO of Intercept Music, Tod Turner. “At Intercept Music, we believe that every artist deserves the opportunity to succeed in the music industry. With our latest update, we are bridging the gap between independent artists and major labels, providing them with sophisticated tools and resources to effectively promote their music and build a loyal fan base.”

To view the full press release, visit https://ibn.fm/gSQFl

About Sanwire Corporation

Sanwire, a diversified company with a focus on technologies for the entertainment industry, has been involved in aggregating technologies for several years. Sanwire looks for opportunities in fragmented markets, where technology can be applied to consolidate services into a single platform of delivery. The company is focused on advanced entertainment technologies. For more information about the company, visit www.SanwireCorporation.com.

NOTE TO INVESTORS: The latest news and updates relating to SNWR are available in the company’s newsroom at https://ibn.fm/SNWR

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, will be participating at this month’s Sidoti & Company Virtual Microcap Conference. The conference is slated for Aug. 17, 2023. During the event, Splash Beverage CEO Robert Nistico will be presenting; his presentation is scheduled to begin at 9:15 a.m. ET. In addition to presenting at the premier event, Nistico will be available for virtual one-on-one meetings with those attending the conference, including potential investors.

To view the presentation, visit https://ibn.fm/2ElSl

To view the full press release, visit https://ibn.fm/YonzM

About Splash Beverage Group Inc.

Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and nonalcoholic beverage brands including Copa di Vino wines by the glass, SALT flavored tequilas, Pulpoloco sangrias, and TapouT performance hydration and recovery drinks. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution. For more information about the company, please visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

• RJD Green announced in May 2023 that its Silex Holdings division had been awarded a major commercial contract worth over $850,000
• For the three months ended May 31, 2023, the company reported revenue of $1.42 million and $290,071 in net operating income
• RJD Green revenue projections for the fiscal year ending August 31, 2023, are $5.1 million, with an expected net profit of $727,250
• The company has monthly recurring revenues of $415,254

RJD Green (OTC: RJDG) is a holding company focused on managing portfolio assets while actively exploring potential acquisitions and opportunities in diversified industries. The company currently operates in three divisions: RJD Green Healthcare Division, Earthlinc Environmental Solutions and Silex Holdings Inc.

The company’s corporate management team has a history of success in both public and private arenas, with diverse enterprise experience that includes RJD Green’s three current market sectors of focus. Corporate overhead is maintained at minimal operating cost, with each officer and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to RJDG are available in the company’s newsroom at https://ibn.fm/RJDG

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

FE Battery Metals (CSE: FE) (OTCQB: FEMFF) (WKN: A2JC89) today announced assay results from newly discovered lithium pegmatite zones to the southeast of its main Augustus exploratory drilling area at the Augustus Lithium Property in Quebec, Canada. According to the update, the assays are from a recently concluded field prospecting, sampling and mapping program completed with a focus on following up drone and airborne geophysical survey targets identified along an approximately 10 km long structural corridor showing four lithium prospects. Among the highlights, the company reported 11 samples over 1% Li2O and two samples over 2% Li2O with a maximum of 2.58% Li2O from a total of 26 samples collected from Augustus East pegmatites near the NAL mine. In addition, three samples are over 0.50% Li2O. “The company is thrilled about these remarkable assay results from our recent exploration efforts in the lithium-rich region of Quebec, Canada,” said FE CEO Gurminder Sangha. “Importantly, this newly discovered lithium-rich area is located a mere 2.9 kilometers from the mineralized pegmatite bodies of Quebec’s largest lithium mine, the North American Lithium (‘NAL’) mine. The company is carrying out an extensive prospecting, mapping and sampling program during this summer. We look forward to providing further updates on our progress as we proceed with our exploration efforts in this highly prospective region.”

To view the full press release, visit https://ibn.fm/34AYI

About FE Battery Metals Corp.

FE Battery Metals is focused on identifying, exploring and advancing early-stage lithium pegmatite projects in Canada. The company’s primary efforts have been on exploration projects located in Quebec, with its flagship property being the Augustus Lithium Property. Augustus is located in the immediate vicinity of Val d’Or Quebec where several historical prospects and a previously active lithium mine is located within a 10km radius from the property. North American Lithium mine (“NAL”) and the Authier Project are two notable projects in the area that highlight the potential of the Augustus Lithium Property.

NOTE TO INVESTORS: The latest news and updates relating to FEMFF are available in the company’s newsroom at https://ibn.fm/FEMFF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, has inked a new agreement with PlanSource, a leading provider of cloud-based benefits administration and engagement technology. The agreement, which expands Dario’s reach in the employer market, calls for the company to offer integrated digital health solutions to more than 5 million consumers. Dario’s proprietary solutions will support employers and their employees address issues such as diabetes, prediabetes, hypertension, and musculoskeletal and behavioral health. Through its unique services, Dario provides highly personalized solutions, which are driven by billions of data insights and are designed to optimize digital and human support. The new agreement enables employers to select and implement Dario’s integrated chronic-condition management solutions with employee health benefit plans to offer a curated set of benefit solutions in the PlanSource Partner Marketplace. “PlanSource and Dario share the same belief that we need to make it easier for employers to adopt new health benefits, especially as they face tremendous pressures in today’s economy,” said DarioHealth president Rick Anderson in the press release. “We are excited to become a part of the PlanSource Marketplace as a way to improve access to Dario’s solutions for employers and employees alike and make better health outcomes possible for everyone.”

To view the full press release, visit https://ibn.fm/56Ulp

About DarioHealth Corp.

DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition digital therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results, and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers and providers of care as well as directly to consumers. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,724,985 to a deuterated psilocybin analog in Cybin’s CYB003 investigational drug program. “We are very pleased to announce this composition of matter patent supporting our clinical-stage CYB003 program, which strengthens our growing intellectual property portfolio and leadership position as a developer of differentiated therapeutics for mental health, especially as we work diligently to advance our clinical trials towards topline data readouts later this year,” said Doug Drysdale, chief executive officer of Cybin. “With this patent granted, we move forward with conviction in our mission of bringing novel, improved treatment options to people suffering from anxiety and depression.”

To view the full press release, visit https://ibn.fm/KqyCO

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Amesite (NASDAQ: AMST), a leading artificial intelligence (“AI”) software company offering a cloud-based learning platform for education, business and government markets, has renewed its partnership with Central Michigan University (“CMU”). According to the announcement, the U.S. continuing ed sector is projected to grow from $60.52 billion in 2022 to $93.25 billion by 2028, with a compound annual growth rate (CAGR) of approximately 7.47%. The announcement noted that there are 474 regional public universities in the United States, and that each one could benefit from launching professional upskilling programs. “Partnership renewals validate our business model,” said Amesite CEO Dr. Ann Marie Sastry in the press release. “Leveraging our state-of-the-art version 6.3 platform with the latest GPT-4 technology and our comprehensive integration capabilities, we are able to launch solutions quickly and efficiently that generate sustainable university revenue in professional learning and drive growth for Amesite.”

To view the full press release, visit https://ibn.fm/Sc7gX

About Amesite Inc.

Amesite delivers its scalable, customizable, white-labeled online learning platform to universities, businesses, museums and government agencies, enabling them to deliver outstanding digital learning. Amesite provides a single system that combines eCommerce, instruction, engagement, analytics and administration using best-in-class infrastructure to serve multibillion-dollar online learning markets. For more information about the company, please visit www.Amesite.io.

NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at https://ibn.fm/AMST

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, has rescheduled its conference call to discuss financial results for the second quarter ended June 30, 2023. The company had initially scheduled the call for Aug. 14, 2023, ET. According to the announcement, specific details regarding the call will be forthcoming. “Vivos expects it will be unable to file its Form 10-Q for the quarter ended June 30, 2023, within the prescribed time period,” the company stated in the press release. “The company and its independent registered public accounting firm require additional time to review certain disclosures related to the company’s accounting for and disclosures related to the company’s Employee Retention Credit previously received under section 2301 of the Coronavirus Aid, Relief, and Economic Security Act of 2020. The company is working diligently to complete its Form 10-Q for such period as soon as possible and currently expects to file the Form 10-Q within the five-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.”

To view the full press release, visit https://ibn.fm/uO4DJ

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective (within the scope of FDA-cleared uses) in the treatment of more than 40,000 patients worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.VivoS.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Siyata Mobile (NASDAQ: SYTA, SYTAW) (TSX.V: SIM), a global vendor of Push-to-Talk (“PTT”) over Cellular (“PoC”) and cellular signal booster solutions, is reporting on its financial results for the three-month period ended June 30, 2023. Highlights of the report include $2.7 million in revenues, a 180% increase from the $970,000 reported for the same period in 2022; gross profit of $804,000, or 29.7% of revenues, compared to $109,000, or 11.2% of revenues, for the three months ended June 30, 2022; net loss came in at ($2.3) million compared to ($4.3) million in the Q2 2022; and Adjusted EBITDA totaled ($2.0) million compared to ($3.4) million in the same period in the prior year. The report also noted that Siyata had $2 million in cash and working capital of $3.7 million at the end of Q2 2023, compared to $1.9 million and $1.6 million, respectively, as of Dec. 31, 2022. In addition, the company reported that in June 2023, it issued 50 million common shares at a purchase price of $0.045 per share in a public offering, resulting in gross proceeds of $2.25 million.

After June 30, 2023, the company effected a 1-for-100 reverse stock split and issued an additional 51.45 million common shares at a purchase price of $0.045 per share in a registered direct offering for gross proceeds of $2.3 million. “Growth continued to accelerate in the second quarter with a 180% year-over-year increase in revenue on strengthening sales of our mission-critical PoC (MCPTT) SD7 solution,” said Siyata Mobile founder and CEO Marc Seelenfreund in the press release. “Adoption of our critical communications devices is expanding. We have received purchase orders for SD7 handset and its accessories of more than $5 million since the start of 2023, and our resellers also anticipate an increase in demand. Just as important, the increase in orders reaches beyond emergency services to include education, healthcare, industrial and enterprise use cases among others. Given our performance in the first half of the year and our expanding sales pipeline, we are increasingly optimistic that 2023 will be a strong growth sales year for Siyata.”

To view the full press release, visit https://ibn.fm/IRsG3

About Siyata Mobile Inc.

Siyata Mobile is a B2B global vendor of next-generation, Push-to-Talk over cellular devices and cellular booster systems. Its portfolio of in-vehicle and rugged devices enable first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to increase situational awareness and save lives. The company’s portfolio of enterprise-grade and consumer cellular-booster systems enables first responders and enterprise workers to amplify cellular signal in remote areas, inside structural buildings where signals are weak and within vehicles for the maximum cellular signal strength possible. For more information about the company, visit www.SiyataMobile.com or www.UnidenCellular.com.

NOTE TO INVESTORS: The latest news and updates relating to SYTA are available in the company’s newsroom at http://ibn.fm/SYTA

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Splash Beverage (NYSE American: SBEV), a portfolio company of leading beverage brands, is reporting its financial results for the second quarter period ended June 30, 2023. Highlights of the report include a 15% increase in quarterly revenue and a 31% increase in six-month revenues as well as a 32% increase in quarterly gross profit and a 34% increase in six-month gross profit. Specifically, net revenues for Q2 period totaled $5.2 million compared to $4.5 million in the prior year period with six-month revenues totaling $11 million compared to $8.4 million in the prior year period. Gross profit for Q2 period reached $1.7 million compared to $1.3 million in the prior year period, with six-month gross profit reported at $3.5 million compared to $2.6 million in the same period 2022 year. In addition, the report noted that SBEV’s TapouT Energy Drink launched during the second quarter. As of June 30, 2023, the company had total cash and cash equivalents of $903,235, compared with $4.4 million on Dec. 31, 2022. “Our 2023 second quarter results reflect the strengths that we are developing as we grow the business as well as some of the challenges that inevitably emerge in growth businesses,” said Splash Beverage chair and CEO Robert Nistico in the press release.

“Our Qplash platform, which has increased 43% in the first half of the year compared to last year, is developing very nicely on both a business-to-business (‘B2B’) and business-to-consumer (‘B2C’) basis and is now expanding to select international markets. We look for continued contributions from that business. Our quarterly beverage revenues were down slightly in the second quarter, but we attribute that to buying patterns of distributors which can have an impact of timing of sales. The first half beverage sales increased modestly at 7% overall, so we expect a greater upward trend the second half of the year. The beverage business generally ‘stair steps’ it’s way to growth . . . you focus on distribution, support those new placements with marketing and the cycle starts over again. In total, we are where we believe we are supposed to be. Subsequent to the second quarter reporting period, we disclosed an additional $2.7 million raise from existing investors and a $10 million credit facility, which will not only provide us with needed growth capital but also allows us to withdraw the much larger $200 million shelf offering, which has been the source of some investor concern. We remain committed to executing a business plan that relies on four key pillars for success. We have a strong management team, we have a diverse portfolio of brands that match consumer trends, our marketing strategy continues to yield new distribution agreements and retail authorizations, and we have the financial flexibility we need. We look forward to the second half of 2023.”

To view the full press release, visit https://ibn.fm/zcAfY

About Splash Beverage Group Inc.

Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and nonalcoholic beverage brands including Copa di Vino wines by the glass, SALT flavored tequilas, Pulpoloco sangrias, and TapouT performance hydration and recovery drinks. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution. For more information about the company, please visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Sigma Additive Solutions (NASDAQ: SASI), a leading provider of quality assurance software to the commercial 3D printing industry, is reporting its financial results for the second quarter ended June 30, 2023. Highlights of the report include Q2 revenues of $97,043 compared to revenues of $236,660 for the same period in 2022; gross profit for the quarter of $60,552 compared to $43,585 for Q2 2022; gross margin for Q2 2023 was 62% compared to gross margin of 18% for the prior year quarter; total operating expenses for second quarter 2023 totaled $1.4 million, compared to $2.3 million in 2022; and net loss for the quarter of was reported at $1.3 million, or $0.12 per share. The company had $0.4 million in cash as of June 30, 2023, with cash used in operating activities for the six months ended June 30, 2023, totaling $2.4 million.

“During the second quarter, we continued our progress reducing expenses and cash burn while working with Lake Street Capital Markets and advisors on the exploration of a variety of strategic alternatives,” said Sigma Additive Solutions president and CEO Jacob Brunsberg in the press release. “We expect our expenses to continue to decrease into the third quarter. In our current report on Form 8-K filed with the SEC on July 20, 2023, we reported that we had received four written, nonbinding proposals to purchase assets or acquire the company in a merger or reverse merger and were in talks regarding the respective proposals, as well as possible alternative transactions with other parties that expressed interest in a possible transaction as we worked to formally close our strategic transaction process. We also reported that we had reduced our headcount to a core team we felt important to a possible sale of the company or all or a portion of its assets and support of current customers and had discontinued our product-development activities and ceased to pursue new customers. Since July 20, 2023, we have received additional written, nonbinding proposals as well as revised previous proposals to purchase certain assets of the company and/or acquire the company in a merger or reverse merger. Although we have not yet entered into any definitive agreements, we are continuing to work towards such definitive agreements with interested parties. We look forward to providing additional updates in the weeks to come.”

To view the full press release, visit https://ibn.fm/ByGpO

About Sigma Additive Solutions

Sigma Additive Solutions is a leading provider of in-process quality assurance (“IPQA”) solutions to the additive manufacturing industry. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D(R) for 3D metal and polymer advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies in real time during the manufacturing process, enabling significant cost savings and production efficiencies by reducing waste, increasing yield and shortening cycle times. Sigma believes its software solutions will be a major catalyst for the acceleration and adoption of industrial 3D printing. For more information about the company, please visit www.SigmaAdditive.com.

NOTE TO INVESTORS: The latest news and updates relating to SASI are available in the company’s newsroom at http://ibn.fm/SASI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

RYVYL (NASDAQ: RVYL), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation to conduct payment transactions, is reporting on its financial and operational results for the second quarter 2023. Highlights of the report include record quarterly revenue of $14.8 million compared to $6.9 million during the same time period in 2022, a 113% increase, and an 85% increase in Q2 processing volume, which totaled approximately $678 million when excluding the sky financial portfolio volume. In addition, the report showed RYVYL’s FX and international payments portfolio processed $425 million in the second quarter compared to $344 million in business volume in Q1 and $121 million in Q2 2022. During the quarter, the company also announced a partnership with Visa to enable Visa Direct to RYVYL’s customers and a partnership with Intercash, a global payment solutions leader, to expand Banking-as-a-Service platform in Europe; in addition, RYVYL EU received approval to launch Single Euro Payments Area (“SEPA”) Instant Payments in Europe. “Business momentum remained strong during the second quarter leading to record quarterly revenue for the third consecutive quarter of $14.8 million, an increase of nearly 113% year over year, exceeding our guidance of $12.5 to $14 million,” said RYVYL CEO Fredi Nisan in the press release.

“This was accomplished on processing volume of $678 million, an increase of 20% from the first quarter 2023 and also above our guidance range of $580 to $610 million. The increased margin profile is a testament to our steadfast focus on improving processing efficiency, workforce and technology. Against the backdrop of regulatory and banking uncertainty in the United States, we see our subsidiary in Europe, RYVYL EU, as a crucial growth driver for us. . . . We view Banking-as-a-Service as the future of global banking and are excited to be an enabling service provider in a space that is rapidly emerging and reaching new customers every day. By the end of the year, we expect to have a full global payments platform covering over one hundred local currencies and local settlements. . . . Looking ahead, given the strength of our Q2 revenue and continuing momentum, we are raising our Q3 revenue outlook to $16 to $18 million. For 2023, we now expect revenue to exceed $60 million on processing volume of $3 to $4 billion. In terms of profitability, we are lowering our Adjusted EBITDA outlook for 2023 to positive $2 to $3 million. With strong growth in our core processing business, improved margin profile, traction with our Banking-as-a-Service offering and steady progress towards our coyni spinoff initiative, we are in the best position we have ever been to generate long-term sustainable value for our shareholders.”

To view the full press release, visit https://ibn.fm/ABjDI  

About RYVYL

RYVYL was born from a passion for empowering a new way to conduct business-to-business, consumer-to-business and peer-to-peer payment transactions around the globe. By leveraging unique blockchain security and USD-pegged stablecoin technology with near real-time attestation, RYVYL is reinventing the future of financial transactions using its coyni(R) stablecoin platform as a transactional foundation. Since its founding as GreenBox POS in 2017, RYVYL has developed applications enabling an end-to-end suite of turnkey financial products with enhanced security and data privacy, world-class identity-theft protection and rapid speed to settlement. As a result, the platform can log immense volumes of immutable transactional records at the speed of the internet for first-tier partners, merchants and consumers around the globe. For more information about the company, please visit www.RYVYL.com.

NOTE TO INVESTORS: The latest news and updates relating to RVYL are available in the company’s newsroom at https://ibn.fm/RVYL

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, is reporting its financial and business results for the quarter ended June 30, 2023. Corporate highlights of the report include initial patient data from UK National Health Service (“NHS”) Miboko Study that indicates weight loss in 100% of participants; sustained development of its proprietary consumer metabolic health platform along with possible deployment as a bolt-on service into existing metabolic and wellness programs; ongoing collaboration with Benchmark Electronics Inc. as a contract manufacturing partner (“CMO”) in developing the manufacture of its proprietary electronic transmitter in anticipation of commercial-sales ramp-up; continued support of its United Kingdom licensee with its application for reimbursement of sensors in the UK; and consistent funding along with the closing of a $6.5 million nondilutive funding in the form of clean debt without any warrants or convertible elements. Financial highlights include R&D expenses totaling $549,012 for the three months ended June 30, 2023; general and administrative expenses reported at $1,508,467 for period ended June 30, 2023; and cash and cash equivalents totaling approximately $4 million for the same period.

To view the full press release, visit https://ibn.fm/M69oX

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark-approved class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a premarket approval application (“PMA”) for sugarBEAT to the U.S. Food and Drug Administration (“FDA”). proBEAT combines noninvasive glucose data processed using artificial intelligence with a digital healthcare subscription service and has been launched in the United States as a general wellness product as part of the company’s BEAT(R) diabetes program that is currently undergoing pilot studies. Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a noninvasive glucose sensor along with an AI mobile application that helps users understand how certain foods and lifestyle habits can impact their overall metabolic health and well-being. Nemaura believes that up to one-half of the population could benefit from a sensor and program that monitors metabolic health and well-being. Nemaura sits at the intersection of the global type 2 diabetes market, which is expected to reach nearly $59 billion by 2025; the $50-plus billion prediabetic market; and the wearable health-tech sector for weight loss and wellness applications, which is estimated to reach $60 billion by 2023. For more information about the company, visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced public offering. The offering was comprised of 4,615,385 shares of the company’s common stock (or common stock equivalents in lieu thereof) as well as warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. According to the announcement, the warrants were immediately exercisable, also at $0.65 per share; the warrants will expire on Oct. 10, 2028. The company announced that gross proceeds from the offering totaled an estimated $3 million, before deducting fees and other offering expenses. 180 Life Sciences anticipates using the funds from the public offering for R&D as well as legal expenses and general corporate purposes, including the preparation of a marketing authorization application for Dupuytren’s Contracture in the United Kingdom and possibly the United States. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.

To view the full press release, visit https://ibn.fm/P1st6

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research and, where appropriate, combination therapy. The company’s current primary focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork